Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Targeted Oncology is Scopus-indexed (Q1, CiteScore 6.9), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Adis.
Checked against the index lists dated .
ISSN 1776-2596Verify ISSN ↗1776-260XVerify ISSN ↗
Publisher: Adis
Cost to publish: About US$4,990 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 85 / 428 | 80th | Q1 |
| Pharmacology (medical) | 57 / 278 | 79th | Q1 |
| Cancer Research | 76 / 233 | 67th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q1, CiteScore 6.9.
Targeted Oncology is Q1 in Oncology (rank 85 of 428), Q1 in Pharmacology (medical) (rank 57 of 278) and Q2 in Cancer Research (rank 76 of 233), by CiteScore 2025.
Targeted Oncology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.9, which places it in quartile Q1 at the 80th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.435, quartile Q1, with an H-index of 65.
The publisher lists an article processing charge of about US$4,990 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Targeted Oncology is published by Adis. Its print ISSN is 1776-2596 and its online ISSN is 1776-260X.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Targeted Oncology has an h-index of 73 and a 2-year mean of 4.81 citations per paper (OpenAlex). Its Scopus CiteScore is 6.9, quartile Q1. On 2-year citations it ranks #62 of 424 Scopus journals in Oncology.
Targeted Oncology published 71 papers in 2025; its busiest recent year was 2024 with 96. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from United States (35%), Japan (9.1%) and Italy (6.9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 4 retracted papers are recorded (3.2 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.